SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Sund Johan)
 

Search: WFRF:(Sund Johan) > Aromatase inhibitor...

  • Sund, Maria,1983-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Oncology,Örebro Univ, Fac Med & Hlth, Dept Oncol, SE-70182 Örebro, Sweden. (author)

Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients : A population-based cohort study

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • Elsevier,2021
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-93128
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-93128URI
  • https://doi.org/10.1016/j.breast.2021.07.004DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-456832URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:147618596URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding agencies:BröstcancerforbundetResearch Council of Region Örebro CountyALF Funding Region Örebro County
  • BACKGROUND: Prior studies regarding use of Aromatase inhibitors (AIs) and risk for cardiovascular disease (CVD) have shown conflicting results. This retrospective cohort study aimed to investigate whether AIs use affects risk for CVD events in postmenopausal breast cancer survivors.METHODS: Using a retrospective cohort study design, four CVD outcomes; heart failure or cardiomyopathy, arrhythmia, acute ischemic heart disease and ischemic stroke or Transient Ischemic Attack were compared with uni- and multivariate Cox regression analyses according to exposure to endocrine therapy (use of AI, tamoxifen or AI/tamoxifen sequentially) or no endocrine therapy.RESULTS: In total 15815 postmenopausal women, surgically treated to early breast cancer during 2006-2012, were included. No significantly increased risk for CVD events was observed in patients with AI use in the whole cohort. However, two subgroup analyses showed increased risk for CVD events in the AI/tamoxifen sequential group; heart failure in patients older than 75 years (Hazard Ratio (HR) 2.44; 95% Confidence Interval (CI): 1.32-4.54) and arrhythmia in patients without prior CVD (HR 1.45; 95% CI: 1.01-2.10). An increased risk for arrhythmia and acute ischemic heart disease in patients with at least four years of AI treatment compared with no or short-time exposure was observed (HR 2.12; 95% CI: 1.40-3.25 for arrhythmia; HR 2.03; 95% CI: 1.15-3.58 for ischemic heart disease).CONCLUSION: Our results indicate an increased risk for ischemic heart disease and arrhythmia in patients treated for more than four years with AIs. This should be considered in the risk-benefit assessment concerning endocrine therapy.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Garcia-Argibay, Miguel,1988-Örebro universitet,Institutionen för medicinska vetenskaper,Clinical Epidemiology and Biostatistics,Örebro Univ, Sch Med Sci, Clin Epidemiol & Biostat, Örebro, Sweden.(Swepub:oru)mlgy (author)
  • Garmo, HansRegional Cancer Center Mellansverige, Uppsala, Sweden; Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK,Reg Canc Ctr Mellansverige, Uppsala, Sweden.;Kings Coll London, Translat Oncol & Urol Res TOUR, Sch Canc & Pharmaceut Sci, London, England. (author)
  • Ahlgren, JohanRegional Cancer Center Mellansverige, Uppsala, Sweden,Reg Canc Ctr Mellansverige, Uppsala, Sweden. (author)
  • Wennstig, Anna-KarinDepartment of Oncology, Sundsvall Hospital, Sundsvall, Swede,Sundsvall Hosp, Dept Oncol, S-85186 Sundsvall, Sweden. (author)
  • Fredriksson, IrmaKarolinska Institutet (author)
  • Lindman, HenrikUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)henrlind (author)
  • Valachis, Antonis,1984-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Oncology,Örebro Univ, Fac Med & Hlth, Dept Oncol, SE-70182 Örebro, Sweden.(Swepub:oru)asvs (author)
  • Örebro universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Related titles

  • In:Breast: Elsevier59, s. 157-1640960-97761532-3080

Internet link

Find in a library

  • Breast (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view